Eli Lilly and Company (LLY)vsRigel Pharmaceuticals Inc (RIGL)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
RIGL
Rigel Pharmaceuticals Inc
$29.22
-4.38%
HEALTHCARE · Cap: $564.75M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 22048% more annual revenue ($65.18B vs $294.28M). RIGL leads profitability with a 124.7% profit margin vs 31.7%. RIGL trades at a lower P/E of 1.6x. RIGL earns a higher WallStSmart Score of 79/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
RIGL
Strong Buy79
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+88.2%
Fair Value
$294.92
Current Price
$29.22
$265.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 186 in profit
Keeps 125 of every $100 in revenue as profit
Strong operational efficiency at 33.2%
Earnings expanding 1599.0% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 124.7% and operating margin at 33.2%. Revenue growth of 21.2% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap.
Key Dynamics to Monitor
RIGL carries more volatility with a beta of 1.27 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RIGL scores higher overall (79/100 vs 78/100), backed by strong 124.7% margins and 21.2% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?